BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia

BACKGROUND: Targeted therapy has always been the focus in developing therapeutic approaches in cancer, especially in the treatment of acute myeloid leukemia (AML). A new small molecular inhibitor, JQ1, targeting BRD4, which recognizes the acetylated lysine residues, has been shown to induce cell cyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yafeng, Zhou, Jianbiao, Lu, Xiao, Tan, Tuan-Zea, Chng, Wee-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042241/
https://www.ncbi.nlm.nih.gov/pubmed/29996811
http://dx.doi.org/10.1186/s12885-018-4661-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042241/
https://www.ncbi.nlm.nih.gov/pubmed/29996811
http://dx.doi.org/10.1186/s12885-018-4661-6

Ejemplares similares